First, we evaluated the abundance of tumor antigen-experienced (CD44hi) CD38-expressing CD8+ T cells in the tumor-bearing host when the tumor size reached ~100 to 120 mm2 (between day 14 and day 15). This evidence concerns the gene CD8A and neoplasm.